UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934. For the period ended DECEMBER 31, 1996
OR
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 934. For the transition period from ------------ to -----------
Commission File Number: 0-12104
---------------------------------------------------------
IMMUNOMEDICS INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 61-1009366
------------------------------- --------------------------------
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
300 American Road, Morris Plains, New Jersey 07950
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip code)
(201) 605-8200
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
[X] Yes [ ]No
Indicate the number of shares outstanding of each of the issuer's classes of
common stock as of the latest practicable date.
As of February 12, 1997, there were 35,988,170 shares of the registrant's common
stock outstanding.
<PAGE>
IMMUNOMEDICS, INC.
INDEX
PART II - OTHER INFORMATION:
Items 1-3 Not applicable
Item 6. Exhibits and reports on Form 8-K
(a) Exhibits
10.24 Consulting Agreement, dated December 16, 1996,
between the Company and Rolf H. Henel.
10.25 License Agreement, dated January 21, 1997, between
the Company and the Center for Molecular Medicine
and Immunology, Inc.
27 Financial Data Schedule
(b) Reports on Form 8-K
The Company did not file a Current Report on Form 8-K
during the three-month period ended December 31, 1996.
SIGNATURES
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
IMMUNOMEDICS INC.
----------------------
(Registrant)
DATE: February 14, 1997 /s/ David M. Goldenberg
-----------------------
David M. Goldenberg,
Chairman, Chief Executive Officer and
Treasurer (Principal Executive Officer
and Principal Accounting Officer)
<TABLE> <S> <C>
<ARTICLE> 5
<CIK> 0000722830
<NAME> IMMUNOMEDICS, INC.
<MULTIPLIER> 1
<S> <C>
<PERIOD-TYPE> 6-MOS
<FISCAL-YEAR-END> JUN-30-1997
<PERIOD-START> JUL-01-1996
<PERIOD-END> DEC-31-1996
<CASH> 3,567,236
<SECURITIES> 17,780,552
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 706,126
<CURRENT-ASSETS> 23,316,023
<PP&E> 10,041,146
<DEPRECIATION> 4,268,961
<TOTAL-ASSETS> 29,088,208
<CURRENT-LIABILITIES> 4,438,860
<BONDS> 0
0
747
<COMMON> 355,200
<OTHER-SE> 24,293,401
<TOTAL-LIABILITY-AND-EQUITY> 29,088,208
<SALES> 797,065
<TOTAL-REVENUES> 1,776,770
<CGS> 7,967
<TOTAL-COSTS> 8,533,007
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (6,756,237)
<INCOME-TAX> 0
<INCOME-CONTINUING> (6,756,237)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (6,756,237)
<EPS-PRIMARY> (0.19)
<EPS-DILUTED> (0.19)
</TABLE>
